Stockscreener 앱 받기
4.28
13.73%
-0.31
전일 마감가:
$4.59
열려 있는:
$4.44
하루 거래량:
5.80M
Relative Volume:
2.99
시가총액:
$299.65M
수익:
$31.25M
순이익/손실:
$-88.48M
주가수익비율:
-2.7613
EPS:
-1.55
순현금흐름:
$-79.63M
1주 성능:
+62.30%
1개월 성능:
+232.77%
6개월 성능:
+232.77%
1년 성능:
+321.19%
1일 변동 폭
$3.67
$4.44
1주일 범위
$2.03
$5.17
52주 변동 폭
$0.77
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ACRS | 3.96 | 299.65M | 31.25M | -88.48M | -79.63M | -1.55 |
| TMO | 512.84 | 195.55B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 233.10 | 166.92B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 128.57 | 36.94B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 194.38 | 35.03B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 418.61 | 33.80B | 3.84B | 866.24M | 792.60M | 9.80 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Equities Analysts Offer Predictions for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Leerink Partners - Defense World
Aclaris Therapeutics director acquires $1.5 million in stock By Investing.com - Investing.com Canada
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Leerink Partnrs - MarketBeat
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies - MSN
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - MSN
S&P 500 Value (IVX) QuotePress Release - The Globe and Mail
Aclaris signs license deal for biologics assets - MSN
Aclaris stock soars for second day on licensing deal, analyst upgrades - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Buy at BTIG Research - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Jefferies Financial Group to “Buy” Rating - Defense World
Aclaris stock sees over 120% upside potential with bolstered immunology assets - Investing.com India
Aclaris Therapeutics Enters Exclusive Agreements and Announces Private PlacementWAYNE, Pa., Nov. 16, 2024 /PRNewswire/ — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has recently entered into significant agreements and a private placement. On Nov - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Raised to “Overweight” at Piper Sandler - Defense World
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG - Yahoo Finance
S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
Aclaris Therapeutics Up 53%; Analysts' Target Boosts Follow Monday License News - MarketWatch
Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha
Aclaris gains global rights to Biosion's inflammatory treatment candidates By Investing.com - Investing.com UK
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps - MSN
Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Aclaris back on track with new money and promising deal - The Pharma Letter
Aclaris Therapeutics secures global rights to Biosion’s antibodies - Yahoo Finance
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Leerink Partners - MarketBeat
Leerink Partners Upgrades Aclaris Therapeutics (ACRS) - MSN
Aclaris Therapeutics upgraded to Outperform from Market Perform at Leerink - TipRanks
Aclaris Therapeutics (NASDAQ:ACRS) Raised to Buy at Jefferies Financial Group - MarketBeat
Jefferies says buy this pharmaceutical play, sees more than 100% upside from here - Head Topics
Aclaris to license Biosion’s two biologics assets for up to $940m - World Pharmaceutical Frontiers
Aclaris stock boosted by BTIG on transformative AD drug acquisition and outlook - Investing.com
Aclaris shares retain Hold rating at Stifel, price target reaffirmed - Investing.com
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo - BioCentury
Aclaris Therapeutics, Inc. announced that it expects to receive funding from a group of investors - Marketscreener.com
Aclaris Therapeutics (ACRS): Strategic Alliance with Biosion Ignites 53% Stock Surge - BP Journal
HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal
Aclaris stock rallies 53% amid licensing deal, Piper upgrade (NASDAQ:ACRS) - Seeking Alpha
Aclaris Therapeutics upgraded to Overweight from Neutral at Piper Sandler - TipRanks
Aclaris secures $80 million in private stock sale By Investing.com - Investing.com Canada
Aclaris shares surge on licensing deal valued at up to nearly $1 billion - The Business Journals
Aclaris (ACRS) Gains Momentum With Strategic Business Expansion - Stocks Telegraph
Biosion sells antibody rights to Aclaris in $940M deal - BioWorld Online
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential - Digital More
Aclaris secures $80 million in private stock sale - Investing.com
Aclaris secures rights to novel immunology biologics - Investing.com
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aclaris Therapeutics Inc 주식 (ACRS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
| Leonard Braden Michael | 10% Owner |
Jul 05 '24 |
Buy |
1.15 |
123,017 |
141,334 |
13,447,969 |
0.69%
2.46%
자본화:
|
볼륨(24시간):